Oxford, UK: In the Times Future of Healthcare supplement, Isansys’ Patient Status Engine (PSE), a smart clinical data collection, analysis and prediction platform, was acclaimed for playing a crucial role in helping care teams around the world combat the Coronavirus. Using real-time patient data to track the course of the disease, the unique clinical infrastructure aims to improve early detection of Covid-19 – and many other conditions – in patients in hospital and home settings.

The PSE uses wearable body-worn sensors to continuously and wirelessly monitor vital signs including heart rate, ECG patterns, respiration rate, blood pressure, temperature and oxygen saturation. Advanced analytic techniques can use these high resolution and highly correlated physiological signals to indicate the presence of the virus, potentially before symptoms are detectable by other methods. These digital biomarkers provide a valuable stream of health data which can enable care teams to better understand the early signs and progression of the disease and respond with more timely and less traumatic interventions.

Keith Errey, CEO of Oxford based Isansys, said: “By providing the technology for in-hospital and remote monitoring of these patients, we are helping shift the paradigm from reactive to proactive care while moving patients from high cost hospital environments to lower cost, safer and less stressful community and home based settings. We have seen a surge in orders of the PSE which has been accelerated by the current pandemic. We are now seeing strong signs that such wireless technologies and data capture and analysis methods will become the standard technology base for the delivery of healthcare in a post-Covid-19 world.”

“This type of technology is not limited to Covid-19 though. The PSE can also be seen as an automation system that can be used across a multitude of applications and clinical areas to enhance patient outcomes, enrich patient experience, improve hospital workflows, increase efficiency and productivity, and provide early warning of deterioration to support hard pressed frontline staff.”

Isansys is currently working with healthcare organisations in the UK, Norway, Denmark, Germany, Italy, Portugal, USA, India, Thailand, Singapore, and Australia.

A future facing and significant feature of the PSE is that it has been designed to maintain its Class II medical device regulatory compliance while being an open platform that is simple to integrate with electronic medical records and other medical data systems. This allows care teams to use the inbuilt Early Warning Scores or develop their own more application focused or disease specific AI based predictive algorithms to look for patterns in the patients’ vital signs that can indicate deterioration or improvement, or act as a digital biomarker or diagnostic. 

To read the full article on Page 16 in The Times supplement click here.